News

Article

Recipharm and Adroit Science Collaborate to Expand Development Services

Adroit Science AB will support Recipharm’s pharmaceutical development with solid-state characterization services.

 

Recipharm AB and Adroit Science AB have formed a new strategic collaboration to expand their service offering. Adroit Science AB will support Recipharm’s pharmaceutical development with solid-state characterization services.  The combination of both companies’ expertise in formulation development, API development, chemical analysis, and solid-state characterization, will improve speed and reduce development costs, while improving quality.

Carl-Johan Spak, executive vice-president, Development & Technology at Recipharm, commented in a press release that the addition of development services from Adroit provides a competitive offering that will help customers to progress their projects more efficiently, including complete development from molecule to product.  Adroit Science AB has established itself as a provider of solid-state characterization services in Northern Europe.

According to Hans Gredeby, CEO of Adroit Science AB, Adroit Science and Recipharm have already cooperated in a number of projects and this partnership marks the next step in the mutual development of both companies’ relationship.

Source: Recipharm

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
Understanding the Operational Impacts of the 15% US-EU Pharma Tariff Cap
Dave Miller, PhD, Chief Scientific Officer, AustinPx